Asahi Songwon Colors Limited — PPTs, 10-05-2025: Investor Presentation

1. Financial Highlights:

Asahi Songwon Colors reported FY25 revenue of ₹562.36 Cr, up from ₹426.24 Cr in FY24. EBITDA surged to ₹56.17 Cr with a margin of 10%, compared to ₹18.26 Cr previously. Profit before tax recovered to ₹24.98 Cr from a loss, and PAT improved to ₹16.86 Cr. Q4FY25 revenue rose 21% YoY to ₹152.75 Cr with EBITDA margin expanding by 420 bps to 11.17%. Net worth stands strong at ₹282.50 Cr, while net debt reduced to ~₹161 Cr from ₹197 Cr, driven by improved cash flows.

2. Strategic Initiatives & Growth Drivers:

Capacity utilization is increasing in Azo pigments and APIs, with expansions ongoing at Dahej and Chhatral. The product range is being diversified beyond blue pigments into red, yellow, and orange Azo pigments and APIs. Investments in R&D focus on efficiency gains and new product development. Export market growth is supported by accreditations for regulatory compliance.

3. Business Developments:

Acquisition of Atlas Life Sciences enhances its pharma API footprint in anti-convulsant and anti-psychotic segments. Commercial API intermediate production has started at Chhatral. A JV with UK-based Tennants Textiles Colours was formed for Azo pigment manufacturing.

4. Market Position & Competitive Advantage:

Asahi leads in phthalocyanine blue pigments in India, serving over 101 customers across 19 countries with ~64% export share. Its advantage comes from long-term clients, zero product returns for 30+ years, and backward integration in CPC Blue crude. Global shifts away from China and its Dahej location add cost and supply chain benefits.

5. Investor Implications:

Capacity ramp-up, product diversification, and China+1 market shifts provide positive growth potential. Margin expansion and deleveraging improve financial health. Risks include competitive pressures in APIs and sustaining operational efficiency. Overall, the company is positioned for steady recovery and value creation.